L19IL2/L19TNF in Skin Cancer Patients

Merkel Cell Carcinoma Clinical Trial

— IntriNSiC  

Official title:

A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05329792
• Other study ID #: PH-L19IL2TNFBASK-04/21
• Status: Recruiting
• Phase: Phase 2
• Start date: March 9, 2023
• Est. completion date: December 2024

Study information

• Verified date: October 2023
• Source: Philogen S.p.A.
• Contact: Lisa Nadal, PhD
• Phone: +39 0577 17816
• Email: regulatory[@]philogen.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.

Description:

Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.

In the study, 70 patients will be enrolled and treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks. The total dose/volume will be distributed among the target lesions defined at screening via single or multiple intralesional injections, according to lesions' size and number.

Tumor assessment:

• Tumor assessment (TA) visits will be performed at Week 12 (Day 78 from the beginning of treatment), then every 8 weeks and up to Week 52 after beginning of treatment. For confirmation of objective responses, unscheduled visits will be performed 4 weeks after the visit, which the objective response was first recorded at.

• During each TA visit, measurement of tumor lesions and documentation (photographic documentation with use of a caliper for cutaneous lesions; ultrasound for subcutaneous lesions; imaging techniques as deemed appropriate/necessary by treating physician) will be performed. The choice of the most suitable instrumental technique to measure and document evolution of the disease will be made by the treating physician at baseline screening, the same technique will have to be used for all following tumor assessments.

• Histological assessment of tumor tissue: estimation of percent of residual viable tumor cells and tumor infiltration with immune responsive cell. Locally performed histological specimen assessment will be centrally reviewed.

After confirmed partial responses, surgery with curative intent is allowed (if considered feasible and of potential benefit for the patients by the treating physician) and will be performed no later than 4 weeks after the TA visit at which the partial response is confirmed.

Safety assessment:

• The safety profile of intratumoral administration of L19IL2/L19TNF will be assessed throughout the study. A complete safety assessment will be performed at the safety visit.

Human-anti-fusion protein antibodies (HAFA) assessment:

• The possible development of antibodies against L19IL2 or L19TNF will be verified. Samples will be collected before L19IL2/L19TNF administration at Days 1, 22 and Day 78 (TA visit).

A Data and Safety Monitoring Board (DSMB), composed of expert dermato-oncologists, will evaluate safety and efficacy data after the first 20 patients and will formulate recommendations for the prosecution of the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: December 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Patient participation to the present study is subjected to the positive evaluation of a local interdisciplinary tumor board, in the context of available treatment alternatives. Whatever the tumor (list of eligible tumors below) the local interdisciplinary tumor board has to consider that a local response to injection of L19IL2/L19TNF may be of benefit for the patient, in the context of this tumor and available therapeutic opportunities, benefit defined by any of the following objectives: (1) to avoid surgery considered difficult or mutilating or (2) as a neoadjuvant treatment with the objective to permit surgery considered initially impossible, or to facilitate surgery considered difficult or mutilating, or to secure surgery considered of uncertain effect or (3) as a salvage treatment to control a tumor proved resistant to treatment alternatives or (4) as a palliative treatment improving patient comfort.

2. Patient must have at least one skin tumor that is amenable to intratumoral injection.

3. All tumors must be histologically confirmed before treatment.

4. Patients with skin tumors eligible to the present study include:

• BCC patients with difficult-to-treat lesions: as defined by EADO operational staging system (stages IIa to IIIb) [1]. Patients must either (i) have already received, or (ii) have progressed after, or (iii) be resistant to, or (iv) not be candidate to all possible alternative treatments, including notably use or re-use of surgery, radiotherapy, hedgehog inhibitors.

• Non-metastatic cSCC patients:

• either advanced SCC for which a simple surgical excision is difficult or impossible, or

• common SCC at high risk of recurrence, for which surgery alone is deemed uncertain by the tumor board, according to EADO /EORTC interdisciplinary guidelines [2]. Patients must either (i) have already received, or (ii) have progressed after, or (iii) be resistant to, or (iv) not be candidate to all possible alternative treatments, including notably use or re-use of surgery, radiotherapy, cetuximab and/or other anti-PD1 checkpoint inhibitors.

• KA: particularly when surgical excision is considered as too much mutilating for this type of tumor

• MCC: particularly when either primary tumor is considered unresectable, or skin metastases or local relapse are primarily or secondarily resistant to anti-PD1 (progress under anti-PD1). Patients must either (i) have already received, or (ii) have progressed after, or (iii) be resistant to, or (iv) not be candidate to all possible alternative treatments, including notably use or re-use of surgery, radiotherapy, and/or any anti-PD1 checkpoint inhibitors.

• CTCL: Tumoral stage of Mycosis fungoides subtypes which are resistant to usual systemic treatments. In order to validate the first inclusion criterion of this trial, the tumor board will take into account that the treatment under investigation is intended to be only a palliative local therapy and cannot compete with a general efficacious strategy, if any.

• KS: Classic or endemic, histologically confirmed KS, particularly when local response can be considered of either functional or cosmetic benefit. In order to validate the first inclusion criterion of this trial, the tumor board will take into account that the treatment under investigation is intended to be only a palliative local therapy and cannot compete with a general efficacious strategy, if any.

• MATS: Advanced or refractory MATS.

5. Subjects must have radiographically or clinically measurable disease, defined as at least one injectable lesion that is = 10 mm in diameter in at least 1 dimension, or an aggregate of injectable lesions that measures = 10 mm in diameter in at least 1 dimension.

6. Subjects must be able and willing to undergo serial biopsies of injected lesion(s) and, when applicable and clinically feasible, non-injected lesions.

7. Male or female patients from the age of 18 years.

8. ECOG Performance Status/WHO Performance Status = 1.

9. Hemoglobin > 10.0 g/dL.

10. Platelets > 100 x 109/L.

11. ALT and AST, GGT and Lipase = 1.5 x the upper limit of normal (ULN).

12. Serum creatinine < 1.5 x ULN and GFR > 60 mL/min.

13. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade = 1 unless otherwise specified.

14. Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomised partner.

15. Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.

16. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

1. Previous or concurrent cancer type that is distinct from the cancers being evaluated in this study, exception made for any other cancer curatively treated = 2 years prior to study entry. Patients suffering from cSCC post-organ transplantation, or cSCC patients with concomitant chronic lymphocytic leukemia are excluded from the study.

2. Previous topical or systemic chemotherapy, immunotherapy, or radiation therapy at the tumor sites within 4 weeks prior to study drug administration.

3. Presence of active severe bacterial or viral infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study. In particular, a documented test for HIV, HBV, HCV and Covid-19 excluding active infection is needed.

4. Impaired cardiocirculatory functions due to any of the following conditions:

1. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.

2. Inadequately controlled cardiac arrhythmias including atrial fibrillation.

3. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).

4. Any abnormalities observed during baseline ECG and Echocardiogram investigations that are considered as clinically significant by the investigator.

5. Uncontrolled hypertension.

6. Ischemic peripheral vascular disease (Grade IIb-IV).

5. Known arterial aneurysms.

6. INR > 3.

7. Known uncontrolled coagulopathy or bleeding disorder.

8. Known hepatic cirrhosis or severe pre-existing hepatic impairment.

9. Moderate to severe respiratory failure.

10. Active autoimmune disease.

11. Patient requires or is taking systemic corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions and asthma/COPD is not considered an exclusion criterion.

12. Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.

13. Pregnancy or breast-feeding.

14. Severe diabetic retinopathy.

15. Recovery from major trauma including surgery within 4 weeks prior to enrollment.

16. Patient with iatrogenic or pathologic severe immune suppression.

17. Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.

Related Conditions & MeSH terms

• BCC - Basal Cell Carcinoma
• Carcinoma
• Carcinoma, Basal Cell
• Carcinoma, Merkel Cell
• Carcinoma, Squamous Cell
• Kaposi Sarcoma
• Keratoacanthoma
• Lymphoma, T-Cell, Cutaneous
• Merkel Cell Carcinoma
• Sarcoma, Kaposi
• Skin Neoplasms

Intervention

Drug:
• L19IL2/L19TNF
Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks

Locations

Country	Name	City	State
France	Hôpital de la Timone	Marseille
France	CHU de Nantes - Hôpital Dieu	Nantes
France	Institut Gustave Roussy	Villejuif
Italy	Istituto Nazionale dei Tumori Fondazione IRCCS	Milano
Italy	IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale"	Napoli
Italy	Istituto Oncologico Veneto IOV	Padova
Italy	Fondazione Policlinico Universitario A. Gemelli Università Cattolica del Sacro Cuore	Roma
Italy	IFO- Istituto Dermatologico San Gallicano	Roma
Italy	IRCCS Istituto Clinico Humanitas	Rozzano	Milano
Italy	Azienda Ospedaliero Universitaria Senese Policlinico Le Scotte	Siena
Italy	Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)	Trieste
Spain	Hospital Clinic Barcelona	Barcelona
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario Virgen Macarena	Sevilla

Sponsors (1)

Lead Sponsor	Collaborator
Philogen S.p.A.

Countries where clinical trial is conducted

France,  Italy,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Confirmed best overall response rate (BORR)	Efficacy of L19IL2/L19TNF measured as Confirmed best overall response rate (BORR) [Complete Response (CR) + Partial Response (PR)] for each tumor type measured according to RECIST v1.1 criteria. Confirmation of CR requires histopathological analysis of exeresis specimens for lesions removed by surgery or of biopsies in all other cases.	Visit will be performed at week 12
Secondary	Disease control rate (DCR)	Disease control rate (DCR) [Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)] for each tumor type measured according to RECIST v1.1 criteria.	Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52
Secondary	Local PFS (LPFS)	Local Progression Free Survival (LPFS) on the treated tumors only	Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52
Secondary	Progression-free survival (PFS)	Progression-free survival (PFS), assessed separately in patients who are not resected after curative intention and in patients who undergo secondary surgery (neoadjuvant intention), whatever the RECIST response to treatment, taking into account appearance of new lesions and occurrence of metastases,	Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52
Secondary	Adverse Events (AE)	Percentage of Patients in Each Treatment Group with AEs, AEs with CTCAE grade =3	From the inclusion in the study (signature of the informed consent form - ICF) until the end of the trial (week 52).
Secondary	Serious Adverse Event (SAEs)	Percentage of Patients in Each Treatment Group with Drug-Related Adverse Events, Serious Adverse Event (SAEs)	From the inclusion in the study (signature of the informed consent form - ICF) until the end of the trial (week 52).
Secondary	Human anti-fusion protein antibodies (HAFA)	Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19IL2 and L19TNF	At week 1, at week 4 and at week 12